Cilostazol in Patients With High Residual Platelet Reactivity After Drug-Eluting Stent Implantation
- PMID: 38300762
- DOI: 10.1097/MJT.0000000000001652
Cilostazol in Patients With High Residual Platelet Reactivity After Drug-Eluting Stent Implantation
Conflict of interest statement
The authors have no conflicts of interest to declare.
References
-
- Long Zhe G, Hau Yu L, Lee DH, et al. Adjunctive cilostazol in patients with high residual platelet reactivity after drug-eluting stent implantation: a randomized, open-label, single-center, prospective (ADJUST-HPR) study. Am J Ther. 2023. [epub ahead of print].
-
- Alemanno L, Massimi I, Klaus V, et al. Impact of multidrug resistance protein-4 inhibitors on modulating platelet function and high on-aspirin treatment platelet reactivity. Thromb Haemost. 2018;118:490–501.
-
- Cheepala SB, Pitre A, Fukuda Y, et al. The ABCC4 membrane transporter modulates platelet aggregation. Blood. 2015;126:2307–2319.
-
- Guarino ML, Massimi I, Alemanno L, et al. MRP4 over-expression has a role on both reducing nitric oxide-dependent antiplatelet effect and enhancing ADP induced platelet activation. J Thromb Thrombolysis. 2021;51:625–632.
-
- Massimi I, Guerriero R, Lotti LV, et al. Aspirin influences megakaryocytic gene expression leading to up-regulation of multidrug resistance protein-4 in human platelets. Br J Clin Pharmacol. 2014;78:1343–1353.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources